Summary DNA ploidy and S-phase fraction (SPF), determined by flow cytometry were studied in 118 patients with muscle-invasive transitional cell carcinoma (TCC) of the urinary bladder, scheduled for cystectomy after pre-operative radiotherapy (20 Gy/l week) with or without systemic cisplatin-based neo-adjuvant chemotherapy. The correlation between these parameters and immunohistochemically demonstrated p53, c-erbB-2 and HCG was also investigated. 
The prognostic role of flow cytometrically (FCM) determined DNA content in superficial bladder cancer has been shown in several reports: DNA aneuploidy or the existence of multiple DNA stemlines were correlated with a high frequency of tumour recurrence, progression and poor survival (Gustafson et al., 1986; Tribukait, 1987; Lipponen et al., 1991; Masters et al., 1989; Norming et al., 1992) . In muscle-invasive bladder cancer the significance of DNA ploidy is less obvious (Lipponen et al., 1991; Jenkins et al., 1990; Jacobsen et al., 1989; Badalament et al., 1990; Wijkstrom et al., 1992; Hug et al., 1992) . Even less is known about the clinical significance of the S-phase fraction (SPF) in muscle-invasive bladder cancer as determined by DNA FCM, though some correlation has been suggested between this parameter and metastatic regional lymph node involvement (Lipponen 1991; Shaaban et al., 1990) or survival (Lipponen et al., 1991; Jacobsen et al., 1992) .
The present study attempts to determine the prognostic significance of DNA ploidy and SPF in patients with operable T2-T4a (UICC, 1978) transitional cell carcinoma (TCC) of the bladder, all of them scheduled for total cystectomy. In addition, the relation of DNA ploidy and SPF to immunohistochemically demonstrated p53 protein (Sidransky et al., 1991, c-erbB-2 protein (Moriyama et al., 1991; Wright et al., 1990; Coombs et al., 1991) and HCG (Iles & Chad, 1991) was studied.
Patients and methods

Patients
From 1980 throughout 1990, 186 patients were referred to the Norwegian Radium Hospital (NRH) for pre-cystectomy oncological treatment of T2-T4a TCC of the urinary bladder. The present series deals with 118 of these patients for whom paraffin blocks of the pre-treatment biopsies could be collected for successful performance of DNA FCM.
The median age of the patients was 66 years (range: 39-80 years) (Table I ). There were 90 males and 28 females. Sixtyseven patients had newly diagnosed bladder cancer (interval from initial diagnosis to start of pre-cystectomy radiotherapy <4 months), whereas 51 patients had been treated for superficial bladder cancer for several months or years before muscle invasion was diagnosed. T categorisation was performed by the referring urologist based on the UICC recommendations (UICC, 1978) .
Treatment
Eleven institutions referred their patients for pre-cystectomy oncological treatment. Radiotherapy was delivered by a linear accelerator (6 or 10 MeV) to parallelly opposed anterior and posterior fields reaching from the lower edge of the foramina obturatoria to the disc between the 5th lumbar vertebra and the sacral bone, the lateral margins including 1 cm of the pelvic wall. The daily fraction was 4 Gy, given from Monday to Friday (total dose: 20 Gy).
In 58 patients radiotherapy was preceded by 2 or 3 threeweekly cycles of cisplatin-based chemotherapy. In the early 1980s this therapy was a part of a feasibility study conducted at the NRH to introduce the idea of neo-adjuvant chemotherapy (23 patients). From 1986 35 patients were entered into the 1st Nordic Cystectomy Trial (Rintala et al., 1992) or had neo-adjuvant chemotherapy with cisplatin, Methotrexate and Velbe (CMV) Schiitte et al. (1985) with slight modifications (Jacobsen et al., 1992) . Briefly, the 100 tm sections were washed twice for 30 min in xylene, then washed in absolute alcohol and rehydrated with decreasing concentrations of alcohol. After centrifugation at 350 g the specimens were incubated overnight with trypsin 0.034% (Sigma T-8128) at 37°C in citrate buffer solution. After filtration through a 60 f.m nylon mesh, the single nuclear suspensions were centrifuged at 350 g for 5 min. Then the specimens were stained with propidium iodide (Vindel0v et al., 1983) .
DNA FCM in nuclear suspensions was performed in a laboratory built flow cytometer based on a Nikon invertoscope and equipped with a mercury lamp of fluorescence optics (Steen & Lindmo, 1979) . The output signals > 580 nm were sorted by a multichannel analyser (Nuclear Data Inc., Illinois), set up in groups of 256 channels and presented as histograms.
Histograms with GO/GI peaks displaying a coefficient of variation (CV) of > 10% were excluded from the final analysis. As internal standards have been shown to be of no value when interpreting DNA histograms from paraffinembedded material (Hedley et al., 1983) , the first distinguishable peak was defined as the DNA diploid GO/G1 peak with a DNA index (DI) of one. If more than one GO/GI peak was present, DNA ploidy was calculated using the DNA diploid GO/GI peak as a reference. A GO/GI peak in the DNA tetraploid region was distinguished from the G2 peak of the diploid cell population by the presence of a G2 peak in the DNA octoploid region, or if it contained more nuclei than the S-phase of the diploid peak. The DNA ploidy regions were defined as DNA diploid (DNA index [DI] 1-1.1), DNA tetraploid (DI: 1.8-2.2) and DNA aneuploid, the region between the DNA diploid and DNA tetraploid range and above the tetraploid region (Hiddemann et al., 1984 
Immunohistochemistry
The pre-treatment biopsies were also paraffin-embedded used for immunohistochemistry by applying the avidin-biotin peroxidase complex (ABC) method (Hsu et al., 1981 
Results
Clinical outcome
The cancer-related 5-year survival for all patients was 60% with no significant difference between the T categories (T2 vs T3/T4a). Stage reduction was seen in 48 patients, 26 of whom had completely tumour-free cystectomy specimens. In patients who had received chemotherapy the 5-year survival rate was 80% as compared to 50% in patients without neo-adjuvant chemotherapy (P = 0.10). the pre-cystectomy T category, the occurrence of stage reduction of the pN category, independent whether DNA diploid tumours were compared with DNA non-diploid TCC or the discrimination was done between TCC with one or with two or more DNA stemlines. Neither was there any correlation between DNA ploidy and survival (Figure 1 ).
S-phase fraction 28
No correlation was found between SPF and the T-or pN 89 category (Table III) neo-adjuvant chemotherapy had been given (P < 0.05, Figure   32 ( 3). This latter finding is consistent with the observation that 42 (1-147)
stage reduction was most often seen in high SPF tumours if 42(1-147) the patients had received neo-adjuvant chemotherapy (Table  IV) . No difference of survival was observed between the SPF groups if no chemotherapy was given (Figure 4 ). (Table V) Months from radiotherapy start Figure 1 Cancer-related survival and DNA ploidy in 118 patients with T3/T2/T4a bladder cancer undergoing pre-operative radiotherapy and total cystectomy ± neo-adjuvant chemotherapy. ( ) number of patients within the subgroup. DNA ploidy determination in paraffin-embedded tumour material yields reliable and reproducible results in our hands. However, some inter-laboratory variation occurs in about 10% of the cases and has to be taken into account when comparing results from different groups (Coon et al., 1988; Fossa et al., 1992) . We found that about 15% of our patients had DNA diploid tumours. This percentage is lower than reported in other series using paraffin-embedded material, including a previous report from our own group (Hug et al., 1992; Malmstr0m et al., 1989; Jacobsen et al., 1987; Badalament et al., 1990) . The DNA diploidy rate of 15% is comparable to the figure of 10% reported by Wijkstrom and when using fresh tumour samples. (Weaver et al., 1990; Jacobsen et al., 1992) . In spite of all uncertainties in determination of SFP in cell suspensions from paraffinembedded material SPF represents a clinical significant parameter in studies in human tumours (Merkel & McGuire, 1990 to be an independent prognostic parameter in patients receiving definitive radiotherapy (Jacobsen et al., 1989) . This finding was not supported by the present series consisting of operable bladder cancer. Our present results are in agreement with our previous findings (Jacobsen et al., 1991 ) and a recent report by Hug et al. (1992) who confirmed that muscle-invasive bladder cancer with DNA diploid stemlines did not display a particularly favourable prognosis as might be expected. Histological grade has in general been shown to correlate with proliferative activity in TCC, consistent with the present observations (Lipponen et al., 1991; Tribukait et al., 1982) . Based on results from DNA flow cytometry in paraffinembedded specimens Lipponen et al. (1991) and Shaaban et al. (1990) have suggested that a high SPF was correlated with the presence of regional lymph node metastases, a finding which is not supported by our results. In a preliminary report we have found a better prognosis for heterogeneously treated patients with advanced bladder cancer and high SPF when chemotherapy was given (Jacobsen et al., 1992) . This observation is confirmed in the present larger and homogeneous series where chemotherapeutically treated patients with high SPF tumours more often experienced stage reduction and had a better prognosis than those with low SPF. The reason may be that high SPF tumours due to their higher proliferation rate respond better to the combined neo-adjuvant onologic treatment (chemotherapy and radiotherapy) than do low SPF tumours. This correlation between SPF and stage reduction/prognosis suggests that patients with high SPF tumours should be offered pre-cystectomy treatment whereas such therapy is less indicated in patients with low SPF tumours.
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The p53 suppressor gene participates in the cell cycle regulation (Levine et al., 1991) . The mutant p53 is assumed to inhibit normal p53 but there is also evidence for a direct oncogenic effect. Most studies suggest that p53 gene mutations arise relatively late in malignant progression. Mutations of the p53 gene have been reported in many human tumours (Porter et al., 1992) . Compared with other series reporting on frequency of the p53 gene mutations or its protein expression in bladder cancer (Sidransky et al., 1991; Porter et al., 1992) a relative high percentage (51%) of p53 protein positive bladder tumours was found in the present study. This might be due to the fact that all patients had muscle-invasive bladder cancer and more than 60% had deeply infiltrating TCC () T3). Fujimoto et al. (1992) have, for example, shown an increase of p53 gene mutations as bladder tumours become muscle-invasive.
We observed a high percentage of p53 positive tumours in the low SPF group, a relation which was maintained even when only p53 protein positive tumours graded as + + or + + + were considered. This observation is intriguing on the background of a recent report by M0rkve and Lhrum (1991) , who found a positive correlation between p53 reactivity and SPF when single cells from lung carcinoma were evaluated simultaneously by FCM. This discrepancy may be due to intra-tumoural heterogeneity and/or methodological differences between M0rkve and Lxrum's observations and the present ones. Further experience in large homogeneous clinical series will be necessary to evaluate the clinical role of p53 in muscle-invasive bladder cancer.
Only about 10% of all bladder tumours in the present series were HCG and c-erbB-2 protein positive. These percentages are lower than reported previously by other groups (Wright et al., 1990; Moriyama et al., 1991; Coombs et al., 1991; Jenkins et al., 1990; Iles & Chard, 1991) , but are consistent with another series from our group (Jacobsen et al., 1990 ). We have not been able to confirm a correlation between DNA non-diploidy and c-erbB-2 protein immunoreactivity as indicated in our previous report on a more heterogeneous series (Berner et al., 1992) .
From the present series we summarise that DNA ploidy does not represent a prognostic parameter in patients who clinically are deemed to have operable muscle invasive TCC of the urinary bladder. However, patients with high SPF tumours seem to benefit from combined neo-adjuvant cytostatic and radiotherapeutic treatment more than those with low SPF tumours. About half of the bladder tumours were p53 protein positive, though the clinical relevance of this finding remains undetermined.
